Mission Therapeutics divested its kidney drug asset MTX652 to Dimerix in a deal worth up to $292 million, aiming to sharpen each company’s development focus. Dimerix will pay $5 million upfront, with additional milestone payments tied to clinical development, marketing approval, and sales. MTX652 targets USP30, a mitochondrial enzyme linked to clearance of damaged mitochondria, and is delivered as an oral once-daily capsule. Mission said it is reallocating resources toward its central nervous system USP30 inhibitor portfolio, including MTX325 for Parkinson’s disease, while Dimerix said the acquisition extends its renal footprint from acute injury to chronic kidney disease. The mechanism is also positioned as a complement to Dimerix’s ongoing kidney programs. Mission highlighted that the USP30 inhibition strategy is intended to restore mitophagy—cellular removal of dysfunctional mitochondria—relevant to both renal injury biology and neurodegeneration.